Search - tctmd.com

Displaying 401 - 420 of 923

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2022

Shelley Wood

May 02, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

News Conference News ACC 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Yael L. Maxwell

April 05, 2022

Presentation ACC 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Presenter: Florian Rader

April 04, 2022

News Conference News ACC 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

Todd Neale

April 04, 2022

Presentation ACC 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presenter: Milind Y Desai

April 03, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

SODIUM-HF: No Impact of Dietary Salt Restriction on Death or Hospitalization

News Conference News ACC 2022

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

L.A. McKeown

April 02, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Daily News

Prognosis of Myocarditis Following COVID-19 Vaccination ‘Favorable’

Michael O'Riordan

March 28, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Daily News

ACC Releases Guidance on CV Issues With COVID-19

Todd Neale

March 16, 2022

More Evidence Links Breast Arterial Calcification and CVD Risk

News Daily News

AI-Based Tool IDs Hypertrophic Cardiomyopathy and Cardiac Amyloidosis

Yael L. Maxwell

February 24, 2022

News Daily News

Even Less-Severe COVID-19 Can Have Long-term CV Effects

Caitlin E. Cox

February 10, 2022

News Daily News

Familial Patterns of Idiopathic Dilated Cardiomyopathy Becoming Clearer

L.A. McKeown

February 10, 2022

News Conference News STS 2022

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Michael O'Riordan

February 04, 2022

News Conference News STS 2022

Modified Surgical MV Repair Stands Up to Replacement

Michael O'Riordan

February 03, 2022

Advertisement

TCTMD’s Top 10 Most Popular Stories for April 2022

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Prognosis of Myocarditis Following COVID-19 Vaccination ‘Favorable’

What’s Going to Be Hot at ACC 2022, In Person or Virtual

ACC Releases Guidance on CV Issues With COVID-19

More Evidence Links Breast Arterial Calcification and CVD Risk

AI-Based Tool IDs Hypertrophic Cardiomyopathy and Cardiac Amyloidosis

Even Less-Severe COVID-19 Can Have Long-term CV Effects

Familial Patterns of Idiopathic Dilated Cardiomyopathy Becoming Clearer

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Modified Surgical MV Repair Stands Up to Replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content